Actinium Pharmaceuticals ATNM
NYSE ATNM
$1.43 +0.05 (+4.03%)
As of: Oct 22, 2026 · 10:03 AM EDT

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023)

Updated

Actinium Pharmaceuticals' Current Deferred Revenue was $100,000 in Q2 2023, down 50.0% from $200,000 a year earlier.

Analysis

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023) Analysis & Trends

At the end of FY2021, Current Deferred Revenue at Actinium Pharmaceuticals came in at $1 million.

  • Quarterly Current Deferred Revenue has moved between $100,000 (Q1 2022) and $1 million (Q4 2021) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,163.48 Bn 1,132.06 Bn 19.71 Bn
2 Johnson & Johnson 631.16 Bn 549.69 Bn 17.26 Bn
3 AbbVie 502.63 Bn 475.74 Bn 12.70 Bn
4 Merck 378.53 Bn 332.91 Bn 12.21 Bn
5 Novartis Ag 302.83 Bn 266.82 Bn 11.24 Bn
6 Astrazeneca 265.92 Bn 239.60 Bn 12.86 Bn
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn
8 Gilead Sciences 194.04 Bn 168.24 Bn 6.22 Bn
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn
10 Actinium Pharmaceuticals 45.06 Mn -134.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 100,000.00
Sep 30, 2022 100,000.00
Jun 30, 2022 200,000.00
Mar 31, 2022 100,000.00
Dec 31, 2021 1.00 Mn
API Access

Actinium Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ATNM&period=max&api_key=YOUR_API_KEY